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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYThe advent of the human-induced pluripotent stem cell (hiPSC) technology has transformed biomedical research, providing new tools
for human disease modeling, drug development, and regenerative medicine. To fulfill its unique potential in the cardiovascular field,
efficient methods should be developed for high-resolution, large-scale, long-term, and serial functional cellular phenotyping of
hiPSC-derived cardiomyocytes (hiPSC-CMs). To achieve this goal, we combined the hiPSC technology with genetically encoded voltage
(ArcLight) and calcium (GCaMP5G) fluorescent indicators. Expression of ArcLight and GCaMP5G in hiPSC-CMs permitted to reliably
follow changes in transmembrane potential and intracellular calcium levels, respectively. This allowed monitoring short- and long-
term changes in action-potential and calcium-handling properties and the development of arrhythmias in response to several pharma-
ceutical agents and in hiPSC-CMs derived from patients with different inherited arrhythmogenic syndromes. Combining genetically
encoded fluorescent reporters with hiPSC-CMs may bring a unique value to the study of inherited disorders, developmental biology,
and drug development and testing.INTRODUCTION
The ability to reprogram adult somatic cells into pluripo-
tent stem cells by a set of transcription factors has
revolutionized biomedical research (Takahashi et al.,
2007; Takahashi and Yamanaka, 2006). The generated hu-
man-induced pluripotent stem cells (hiPSCs) can be coaxed
to differentiate into a variety of cell lineages (including
cardiomyocytes [Zhang et al., 2009; Zwi et al., 2009]) that
can then be utilized for the development of autologous
cell-replacement therapies, disease modeling, and drug
discovery (Robinton and Daley, 2012).
In the cardiac field, hiPSC lines were established from
healthy individuals (Zhang et al., 2009; Zwi et al., 2009)
and from patients inflicted with acquired (heart failure)
(Zwi-Dantsis et al., 2013) and inherited cardiac disorders.
Among the latter, patient-specific hiPSC-derived cardio-
myocytes (hiPSC-CMs) models of different inherited ar-
rhythmogenic syndromes (Bellin et al., 2013; Caspi et al.,
2013; Itzhaki et al., 2011a, 2012; Jung et al., 2012; Moretti
et al., 2010) and diverse cardiomyopathies (Lan et al., 2013;
Sun et al., 2012) were established. The patient/disease-spe-
cific hiPSC-CMs were shown to recapitulate the disease
phenotypes in culture, to provide mechanistic insights
into disease processes, and to evaluate existing and novel
therapies. Similarly, hiPSC-CMs were also proposed as a
valuable tool for drug development (Mercola et al., 2013),
demonstrating, for example, their value for safety pharma-
cology by screening the proarrhythmic effects of certain582 Stem Cell Reports j Vol. 5 j 582–596 j October 13, 2015 j ª2015 The Acompounds (Braam et al., 2013; Liang et al., 2013; Zwi
et al., 2009).
One of the key prerequisites for achieving the goals of
these applications is to develop efficient tools to study
the functional properties of the hiPSC-CMs and specifically
of their electrophysiological and excitation-contraction-
coupling properties. To this end, different electrophysio-
logical techniques (patch-clamp (Itzhaki et al., 2011a)
and multielectrode extracellular potential recordings [Zwi
et al., 2009]) and imaging modalities (using voltage- or
calcium-sensitive fluorescent dyes) were utilized. While
providing valuable information, these methodologies
also display inherent limitations, such as relatively low-
throughput (patch-clamp), limited electrophysiological
information (extracellular recordings), phototoxicity
(voltage and calcium sensitive dyes), and inability to obtain
long-term repeated recordings (patch-clamp, fluorescent
dyes). Consequentially, a method that allows long-term,
serial, and cellular functional phenotyping of healthy
and diseased hiPSC-CMs is direly needed, especially if it
can be achieved in a non-invasive, high-resolution, and
large-scale manner.
The developments in the field of genetically encoded
fluorescent indicators may provide a possible solution to
the aforementioned challenges. Genetically encoded indi-
cators are composed of a sensing element, which is usually
fused to an autofluorescent protein (like circularly
permuted enhanced GFP; cpEGFP) that alters its fluores-
cent intensity as a result of conformational changes inuthors
the sensing element. While utilized in numerous neurosci-
ence-related experimental models (Akemann et al., 2010;
Cao et al., 2013; Grienberger and Konnerth, 2012; Looger
andGriesbeck, 2012; Tian et al., 2009), the use of similar in-
dicators in non-neuronal tissues, such as the heart, has
been more limited (Addis et al., 2013; Chong et al., 2014;
Kaestner et al., 2014; Leyton-Mange et al., 2014). Here,
we aimed to transfer these emerging technologies to the
cardiac field, specifically focusing on genetically encoded
calcium indicators (GECIs) (Grienberger and Konnerth,
2012; Kaestner et al., 2014; Tian et al., 2009) and geneti-
cally encoded voltage indicators (GEVIs) (Jin et al., 2012;
Kralj et al., 2012; Leyton-Mange et al., 2014), in an attempt
to establish experimental platforms to monitor the func-
tional activity of hiPSC-CMs. To this end, we aimed to ex-
press GCaMP5G (Addis et al., 2013; Tian et al., 2009), a
GECI that displays improved dynamic range, improved
sensitivity, and maintains relatively stable expression
levels, and ArcLight A242 (Cao et al., 2013; Jin et al.,
2012; Leyton-Mange et al., 2014), a new variant of the
Ciona intestinalis voltage-sensitive (CiVS)-based fluores-
cent protein voltage sensor (Barnett et al., 2012; Murata
et al., 2005) super-family, in both healthy and diseased
hiPSC-CMs.RESULTS
Expression of ArcLight in hiPSC-CMs
Dermal fibroblasts from a healthy individual were reprog-
rammed to generate hiPSCs by retroviral delivery of
SOX-2, KLF-4, and OCT4. The generated hiPSC colonies
displayed characteristic morphology, expressed the plurip-
otencymarkers NANOG, SSEA4, OCT-4, and TRA-1-60 (Fig-
ure S1A), and maintained a normal karyotype (Figure S1B).
Pluripotency of the hiPSCs was verified by the presence of
cell derivatives of all three germ layers in differentiating EBs
(Figure S1C) and by formation of teratomas in SCID-beige
mice (Figure S1D). Finally, hiPSCs showed silencing of
the three retroviral transgenes (Figure S1E) and reactivation
of endogenous pluripotency genes NANOG, SOX2, and
OCT4 (Figure S1F).
Cardiomyocyte differentiation of the hiPSCs was
achieved using a modification of the monolayer-based
directed differentiation system (Wang et al., 2014). This re-
sulted in efficient differentiation with the percentage of
cardiac troponin I (cTnI)-positive cells, ranging from 80%
to 95% in the different hiPSC lines used. Gene expression
analysis revealed the expression of cardiac-specific genes
(NKX2.5, MLC-2V, MYH-6, and MYH-7) by the hiPSC-CMs
and the downregulation of pluripotent genes (Figure S1G).
Immunostaining studies showed positive staining for sar-
comeric a-actinin and cTnI (Figure S1H).Stem CellThe hiPSC-CMs were dispersed into single cells by enzy-
matic dissociation and plated on Matrigel-coated cover-
slips. Lentiviral transduction was used to deliver the
ArcLight transgene to the plated cells, resulting in robust
expression of the fluorescent reporter (Figure 1A). Impor-
tantly, as shown in Movie S1, the fluorescence levels of
the ArcLight-expressing hiPSC-CMs changed during the
cardiac cycle, with a reduction in fluorescence intensity
concomitant with membrane depolarization (during the
action potential), followed by a rise in fluorescence during
membrane repolarization and at the resting state.
To quantify the fluorescence changes, we utilized the
line-scan mode of the confocal microscope (Figures 1A–
1C). The optical signals derived were highly stable, allow-
ing continuous recordings of several optically derived
action potentials (APs) from the same cardiomyocyte (Fig-
ure 1B) and detailed characterization of each sampled AP
(Figure 1C). Interestingly, similar to previous reports using
intracellular recordings (Zhang et al., 2009), three types of
hiPSC-CMs’ optical APmorphologies were noted (ventricu-
lar-, atrial-, and nodal-like; Figure 1D), suggesting the pres-
ence of different cardiomyocyte subtypes.
Monitoring the Effects of Ion-Channel Modulators
Next, we evaluated the ability of ArcLight to detect changes
in the APmorphology of the hiPSC-CMs, focusing on alter-
ations in AP duration (APD) because of the importance of
this parameter for modeling inherited arrhythmogenic
syndromes (short and long QTsyndromes) and for the field
of cardiac safety pharmacology. To this end, we applied spe-
cific ion-channel modulators designed to either block the
slow (IKs) or fast (IKr) components of the delayed rectifier
potassium current or to augment the late-sodium current
(INaL), simulating alterations in currents most relevant to
the congenital long QT syndrome types 1, 2, and 3,
respectively.
Application of the IKr blocker E4031 (500 nM) led to sig-
nificant prolongation of the optical APD (Figure 1E, top
left) in the hiPSC-CMs with APD90 (time to 90% repolariza-
tion), increasing from 329 ± 22ms to 571 ± 66ms (p < 0.01,
n = 27; Figure 1E, right). Interestingly, E4031 was highly ar-
rhythmogenic in many hiPSC-CMs (48%), leading to
development of early afterdepolarizations (EADs) and trig-
gered beats (Figure 1E, bottom). Similarly, blocking of IKs
with chromanol-293B (30 mM) also prolonged APD90 in
the hiPSC-CMs (p < 0.01, n = 29, Figure 1F). Consistent
with the notion that IKs does not play as an important
role in hiPSC-CMs repolarization as IKr, the arrhythmias
induced by chromanol were significantly less frequent
with only 3% of the cells displaying EADs. Finally, applica-
tion of ATX-II (30 nM), known to augment INaL, also led to
marked APD90 prolongation (p < 0.01, n = 28; Figure 1G),
which was associated with arrhythmogenic activity inReports j Vol. 5 j 582–596 j October 13, 2015 j ª2015 The Authors 583
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Figure 1. ArcLight Expression and Imaging
(A) Lentiviral transduction of the hiPSC-CMs led to robust ArcLight expression, manifested by cyclic changes in the cell fluorescence with
reduced intensity during depolarization. Scale bars, 20 mm.
(B and C) Optical APs derived from line-scan imaging of ArcLight-expressing hiPSC-CMs.
(D) Optical APs revealing ventricular-, atrial-, and nodal-like AP morphologies.
(E–G) Changes in AP morphologies (top-left images, red signals depict post-treatment tracings), following the application of blockers of
the fast (E4031, 500 nM, n = 27 in three independent experiments, E) and slow (Chromanol293B, 30 mM, n = 29 in three independent
experiments, F) components of the delayed rectifier potassium currents and activator of the late-sodium current (ATX-II-30nM, n = 28 in
three independent experiments, G). All agents caused significant APD90 prolongation (right) and development of EADs and triggered beats
(lower). *p < 0.01 when compared to baseline values.
(H) No significant differences were noted after control-solution application (DMSO 0.1% v/v, n = 16 in three independent experiments).
Error bars represent SEM.61% of the cells (Figure 1G, bottom). In contrast, applica-
tion of vehicle-control solution (DMSO-0.1% v/v) did not
alter APD90 or induce EADs in the tested cells (from 378 ±
31 to 374 ± 35, n = 16; Figure 1H).
Generation of Stable ArcLight-Expressing hiPSC
Clones
While lentiviral transduction led to robust expression of
ArcLight and allowed long-term analysis of the hiPSC-
CMs, it requires repeating the process for any new batch of
hiPSC-CMs studied. To overcome this limitation, we aimed
to generate a stable transgenic hiPSC line that continuously584 Stem Cell Reports j Vol. 5 j 582–596 j October 13, 2015 j ª2015 The Aexpresses ArcLight. Undifferentiated hiPSCs were trans-
duced with a lentiviral vector encoding for ArcLight under
thecontrolof a constitutivepromoter,CAG.The transduced
hiPSC colonies were propagated and further enriched using
fluorescence-activated cell sorting selection based on
ArcLight fluorescent levels. This resulted in an increase in
the mean proviral integration from 9.7 to 12.7 copies/cell.
This process also allowed derivation of relatively homoge-
neous hiPSC clones (Figure 2A), showing high ArcLight
expression levels even after several passages (Figure 2A).
The generated ArcLight-hiPSC clones maintained a
normal karyotype (Figure S2A) and continued to fulfilluthors
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Figure 2. Establishment of Stable Transgenic ArcLight-hiPSCs
(A) Expression of ArcLight (green fluorescence) by undifferentiated ArcLight-hiPSC colonies (top), but not by the parental hiPSC colonies
(bottom). The merged light (DIC) and fluorescent images (right) are also shown. Scale bars, 50 mm.
(B) Immunostaining of ArcLight-hiPSC colonies for OCT4, NANOG, SSEA4, and TRA-1-60.
(C) Immunostaining of ArcLight-hiPSC-CMs for sarcomeric a-actinin and cTnI.
(D) qPCR analysis of ArcLight-hiPSC-CMs showing expression of cardiac-specific genes (NKX2.5, MLC-2V, MYH-6, and MYH-7) and down-
regulation of pluripotent genes (OCT4 and NANOG). Experiments included three biological replicates measured as two technical replicates.
(E and F) ArcLight expression by hiPSC-CMs monolayers (E) and single-dispersed cells (F) and the derived optical AP. Note the increase in
fluorescence during repolarization (resting state) and the decreased intensity during depolarization (AP development). Scale bar, 20 mm.
(G) Optical tracings analysis used to measure APD90. This process can be scaled up to analyze several cells (bottom).
Error bars represent SEM.
See also Figure S2.the criteria defining hiPSCs, including expression of
different pluripotent markers (Figure 2B), differentiation
into cell derivatives of the three germ-layers both in vitro
(Figure S2B) and in vivo (Figure S2C), silencing of the
three retroviral transgenes (Figure S2D), and reactivation
of endogenous pluripotency genes (Figure S2E). The
ArcLight-hiPSCs could be efficiently coaxed to differentiate
into cardiomyocytes (Movie S2). Gene expression and im-
munostaining studies revealed expression of cardiac-spe-
cific genes by the ArcLight-hiPSC-CMs at both the mRNA
and protein (Figures 2C and 2D) levels, while confirming
continued expression of the ArcLight reporter (Figures 2E
and S2F). Importantly, ArcLight fluorescent levels in theStem CellhiPSC-CMs monolayers cyclically changed during the
cardiac cycle (Figure 2E; Movie S3). Note the decrease in
fluorescent intensity (during membrane depolarization)
that immediately precedes the eventual cells contraction.
Confocal line scans of dispersed single-cell ArcLight-
hiPSC-CMs showed typical optical APs (Figure 2F).
This allowed acquisition of optical signals from several
ArcLight-hiPSC-CMs and quantitative analysis of the distri-
bution of AP-derived parameters (such APD90) from a large
population of cells (Figure 2G). Importantly, while the use
of voltage-sensitive dyes may be hampered by cellular
toxicity and reduced photostability, the optical signals
derived from the ArcLight-hiPSC-CMs were highly stableReports j Vol. 5 j 582–596 j October 13, 2015 j ª2015 The Authors 585
A E
B G
C D H
F
Figure 3. Simultaneous ArcLight and di-8-ANEPPS Recordings from hiPSC-CMs
(A) Short-term recordings revealing stable optical APs over a 1 hr period (left). Note also the stable APD90 values (right, n = 14 in three
independent experiments). See also Figure S3A.
(B) Repeated phenotyping of the same cell over several days.
(C) Optical APs acquired simultaneously using ArcLight (black tracing) and di-8-ANEPPS (red tracing).
(D) High correlation (R2 = 0.98) between ArcLight- and di-8-ANNEPS-based APD90 measurements from the same cells.
(E) Improved signal-to-noise ratio (SNR) values in the ArcLight optical signals when compared to di-8-ANNEPS analysis (*p < 0.001, n = 17
in three independent experiments).
(F) Changes in the optical-signal intensity at 15 and 30 s of continuous imaging. Note the significant attenuation of the di-8-ANEPPS
signal (due to photobleaching) in contrast to the limited effect on the ArcLight signal (*p < 0.001, n = 17 in three independent
experiments).
(G) Optical APs recorded from ArcLight-hiPSC-CMs during pacing at different rates.
(H) Restitution plot depicting the effects of the pacing cycle-length on APD90 values (n = 7 in three independent experiments). Note the
typical shortening of APD90 values at faster rates.
Error bars represent SEM.(Figures 3A and 3B), without any obvious signs of toxicity.
This allowed continuous acquisition of optical APs for
prolonged periods, both acutely (Figure 3A) and during
repeated cellular phenotyping of the same cells over several
days (Figure 3B).
In further validation experiments, we loaded the
ArcLight-hiPSC-CMs with the voltage-sensitive dye, di-8-
ANEPPS. Fluorescence emission was then split using a
dichroic mirror and collected by two photomultipliers
simultaneously. When comparing the ArcLight optical sig-586 Stem Cell Reports j Vol. 5 j 582–596 j October 13, 2015 j ª2015 The Anals (black tracing in Figure 3C)with those derived from the
voltage-sensitive dye (red-tracing), we noted a relatively
good correlation between the two signals. This was mani-
fested by a high correlation (R2 = 0.98) between the APD90
values measured by bothmethods from the same cells (Fig-
ure 3D). However, similar to previous reports in neurons
(Jin et al., 2012) and hESCs-CMs (Leyton-Mange et al.,
2014) suggesting a delayed response of ArcLight at high fre-
quencies, the phase 0of theArcLightoptical APwas delayed
compared to the di-8-ANEPPS signal (Figure 3C).uthors
Importantly, ArcLight optical imaging of hiPSC-CMs was
superior to di-8-ANEPPS in terms of the signal-to-noise ra-
tio (SNR; Figure 3E) and in the stability of the optical signal
over time (Figure 3F). Thus, while the di-8-ANEPPS signal
was attenuated by 53% ± 4% and 66% ± 5%, due to photo-
bleaching at 15 and 30 s of imaging, respectively, the
ArcLight signal was reduced by only 2% ± 0.3% and 4% ±
0.5% (n = 17; p < 0.001; Figure 3F). ArcLight imaging was
also less toxic to the hiPSC-CMs with 97.7% of the cells
(n = 10 experiments involving 121 cells) continuing to
beat at 3 hr following imaging in contrast to only 67.4%
following di-8-ANEPPS imaging (n = 7 experiments with
70 cells; p < 0.001; Figure S3A).
Finally, we also evaluated the hiPSC-CMs’ AP properties
during pacing (using field stimulation) at different rates
(Figure 3G). This allowed derivation of restitution curves,
evaluating changes in AP properties (APD90) in the same
cells as function of beating frequency (n = 7; Figure 3H).
Note in the plot, the typical shortening of APD90 at faster
pacing rates.
Drug Testing Using ArcLight-hiPSC-CMs
Next, we evaluated the ability to use ArcLight-hiPSC-CMs
for drug testing and specifically in the area of safety phar-
macology. Drug-induced AP prolongation may lead to
life-threatening arrhythmias and represents the single
most important reason for withdrawal of already approved
drugs from the market (Roden, 2004). To evaluate the
ability to discern such drug effects, we studied clinically
relevant drugs known to prolong the QT interval in the
electrocardiogram (the clinical correlate of APD) and to
be associated with pro-arrhythmia due to their hERG
channel (IKr) blocking activity.
Cisparide is an antiemetic drug that was withdrawn from
the market due to its potent hERG-blocking activity that
led to arrhythmias and sudden death. Application of cisapr-
ide (100 nM) to the ArcLight-hiPSC-CMs led to significant
APD90 prolongation from 355 ± 21 to 410 ± 25 ms (n = 15,
p < 0.01; Figure 4A) and to the development of EADs in 27%
of the cells (Figure 4A, right). Significant APD90 prolonga-
tion (from 396 ± 19 to 588 ± 59 ms, n = 29, p < 0.01) and
development of EADs (14% of cells) were also observed
following application of 30 mM erythromycin (Figure 4B),
an antibiotic known to prolong QT interval and elicit ar-
rhythmias in susceptible individuals. Similarly, application
of sotalol, a class III anti-arrhythmic agent directly inhibit-
ing IKr, also led to APD90 prolongation (from 444 ± 50 to
645 ± 56 ms, n = 22, p < 0.01; Figure 4C) and development
of EADs in 36% of the ArcLight-hiPSC-CMs.
We also attempted to detect drug-induced QT changes
that are not related only to direct IKr blockade but are the
result of multi-current interactions. Tyrosine kinase inhib-
itors (TKIs) have become the treatment of choice for multi-Stem Cellple cancer types. However, unexpected cardiotoxicity has
arisen in some patients, which may be related to down-
stream effects on multiple ion currents as suggested by a
recent study in canine cardiomyocytes (Lu et al., 2012).
To test the ability to detect such effects by TKIs, we applied
nilotinib (1 mM) for 1 hr, which led to significant APD90
prolongation (from 470 ± 36 to 821 ± 79 ms, n = 17, p <
0.01) and development of EAD in 18% of the ArcLight-
hiPSC-CMs (Figure 4D).
Evaluation of LQTS-hiPSC-CMs with ArcLight
To evaluate the ability to use ArcLight for studying diseased
hiPSC-CMs, we utilized a disease-specific hiPSC line, previ-
ously derived from a patient with the long QT syndrome
type 2 (LQTS2) (Itzhaki et al., 2011a). LQTS2-hiPSCs were
differentiated into cardiomyocytes (Figure 5A), dispersed
into single cells, and lentivirally transduced to express
the ArcLight reporter. ArcLight optical recordings could
identify the major LQTS abnormality in the LQTS2-
hiPSC-CMs, namely, prolonged APD (Figure 5B). Thus,
the mean optical APD90 was significantly longer (p <
0.01) in the LQTS-hiPSC-CMs (1,041 ± 58 ms, n = 97)
when compared to healthy control hiPSC-CMs (408 ±
8 ms, n = 203). These values are consistent with previously
reported patch-clamp recordings from the same cells
(Itzhaki et al., 2011a). However, in contrast to the low-
throughput nature of patch-clamping, ArcLight imaging
permitted screening of several cells. This allowed, for
example, comparing APD90 values in hiPSC-CMs clustered
into groups according to their different beating rates. This
analysis revealed significantly longer APD90 values in
LQTS2-hiPSC-CMs when compared to healthy control
cells at all beating frequencies, but especially at slow rates
(Figure 5C). Finally, LQTS2-hiPSC-CMs were highly ar-
rhythmogenic, with 53% of the cells (n = 165) showing
EADs, triggered beats, and even continuous arrhythmo-
genic activity (Figure 5D).
Expression of GCaMP5G in hiPSC-CMs
Next, we shifted our focus to calcium handling and evalu-
ated the ability to monitor intracellular calcium transients
in hiPSC-CMs with GECIs. We used lentiviral transduction
to express the GCAMP5G transgene (under control of the
cTnT promoter) in dispersed single-cell hiPSC-CMs (Fig-
ure 6A). Notably, GCaMP5G fluorescence in the imaged
hiPSC-CMs cyclically changed (Figure 6A; Movie S4) with
an increase in fluorescence intensity during the systolic
rise in intracellular calcium levels, followed by a reduction
in fluorescence during relaxation. A line-scan evaluation of
the GCaMP5G-hiPSC-CMs allowed continuous recordings
of several optically derived calcium transients from the
same cardiomyocyte over time and detailed morphological
analysis of each signal (Figure 6C).Reports j Vol. 5 j 582–596 j October 13, 2015 j ª2015 The Authors 587
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Figure 4. Drug Testing Using ArcLight-hiPSC-CMs
(A–C) Evaluating the effects of different hERG (IKr) blockers, including cisapride (100 nM, n = 15 in three independent experiments, A),
erythromycin (30 mM, n = 29 in three independent experiments, B), and sotalol (20 mM, n = 22 in three independent experiments, C) on the
optical APs of ArcLight-hiPSC-CMs. Note the resulting AP prolongations (red tracings, left), leading to significant increases in APD90 values
(middle) and the development of EADs in several (27%, 12%, and 36%, respectively) hiPSC-CMs (right). *p < 0.01 when compared to
baseline recordings.
(D) AP prolongation (left and middle) and arrhythmogenic activity (right) in ArcLight-hiPSC-CMs, following 1 hr treatment with the TKI
nilotinib (1 mM, n = 17 in three independent experiments, *p < 0.01).
Error bars represent SEM.In further validation experiments, we loaded the
GCaMP5G-expressing hiPSC-CMs with the calcium-sensi-
tive dye Rhod-3.When comparing theGCaMP5 optical sig-
nals (black tracing in Figure 6C) with those of Rhod-3 (red
tracing in Figure 6C) from the same cells, we noted a good
correlation between the two methods (Figures 6C and 6D;
Movie S5). However, the calcium transient rise time in
the GCaMP5G signal (277 ± 21 ms, n = 18, p < 0.01) was
slightly longer than in the Rhod-3 signal (218 ± 23 ms; Fig-
ure 6D, left). The transient decay constant was not signifi-
cantly different between the two methods (757 ± 49 and
695 ± 64, respectively; Figure 6D, right). Importantly,
when compared to Rhod-3 imaging, the GCaMP5G optical
calcium transients had a higher signal-to-noise ratio (Fig-
ure 6E), were highly stable (Figure 6F, top), and displayed
both larger DF/F0 values (p < 0.01; Figure 6F, bottom left)
and greater photostability (Figure 6F, bottom right). Thus,
while the Rhod-3 signal decreased by more than 20% for588 Stem Cell Reports j Vol. 5 j 582–596 j October 13, 2015 j ª2015 The Aevery minute, the corresponding GCaMP5G signal was
reduced by only 1.5% (p < 0.01; Figure 6F, bottom right).
Drug Testing Using the GCaMP5G Reporter
Next, we evaluated whether the GCaMP5G-hiPSC-CMs
can be used for drug testing. Initially, we evaluated the abil-
ity to trace potential chronotropic changes. Application of
the beta-adrenergic agonist isoproterenol (1 mM) increased
the beating rate of the hiPSC-CMs (Figure 6G, middle) as
manifested by a significant decrease in their mean cycle
length by 61% (n = 21, p < 0.01, Figure 6G, bottom). Isopro-
terenol also led to significant shortening of the signal rise
(by 12%, p < 0.05) and decay (by 42%, p < 0.01) times, indi-
cating faster activation and to a greater extent more rapid
relaxation (Figure 6G, bottom).
Next, we studied drugs known to alter calcium handling
in cardiomyocytes. Ouabin is a sodium/potassium ATPase
blocker that can lead through a cascade of events touthors
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Figure 5. ArcLight Imaging of LQTS2 hiPSC-CMs
(A) Differentiation of the LQTS2-hiPSCs (representative colony shown on the left; scale bar, 100 mm) into cardiomyocytes, positively
stained for sarcomeric a-actinin (middle) and cTnI (right). Scale bars, 20 mm.
(B) ArcLight imaging showing prolonged optical APs in the LQTS2-hiPSC-CMs (bottom) when compared to healthy control cells (top).
(C) Summary of the average APD90 values, measured at different beating rates, in the healthy control (blue, n = 203 in 19 independent
experiments) and LQTS2 (red, n = 97 in 11 independent experiments) hiPSC-CMs. Note the significantly longer (*p < 0.01) APD90 values in
the LQTS2-hiPSC-CMs at all rates, but especially at slow beating rates.
(D) Typical recordings from the LQTS2-hiPSC-CMs showing the development of EADs, triggered beats, and sustained arrhythmogenic
activity.
Error bars represent SEM.intracellular Ca2+ accumulation, activation of the mem-
brane sodium/calcium exchanger (NCX), development of
delayed-after-depolarizations (DADs), and triggered activ-
ity. Application of ouabin to the GCaMP5G-hiPSC-CMs re-
sulted in a dose-dependent pro-arrhythmic effect. 500 nM
ouabin led to development of DADs, occasional triggered
beats, and double- and triple-humped calcium transients
(Figure 6H, middle). Increasing the ouabin dose to 1 mM
worsened this arrhythmogenic activity with each individ-
ual calcium transient followed by a series of repeated trig-
gered-events (Figure 6H, bottom panel).
Combined Voltage and Calcium Imaging
Next, we evaluated the feasibility of simultaneously moni-
toring, in the same cell, changes in membrane voltage andStem Cellintracellular calcium levels. A potential hurdle in using
combined ArcLight and GCaMP5 imaging for such a task
is that both reporters use changes in cpEGFP fluorescence
as their functional output. To overcome this limitation,
we initially used ArcLight as the voltage reporter and the
calcium-sensitive dye, Rhod-3, for calcium imaging. As
shown in Figure 6I, this allowed simultaneous acquisition
of the optically derived AP (black tracing) and intracellular
calcium transient (red), with the calcium transient peak
typically lagging behind the voltage changes.
To perform combined calcium and voltage imaging using
a dual genetically encoded indicator system, we replaced
ArcLight with an alternative GEVI. Arch(D95N) is a micro-
bial rhodopsin-based voltage indicator with fast kinetics
and red-shifted excitation and emission spectra (KraljReports j Vol. 5 j 582–596 j October 13, 2015 j ª2015 The Authors 589
et al., 2012). As depicted in Figures 6J and S3B, the com-
bined line-scan imaging of Arch(D95N) and GCaMP5G
allowed us to simultaneously acquire both the optically
derived AP (black tracing) and the calcium transient (red).
This permitted us to capture arrhythmogenic events that
can be identified in by both the calcium and voltage optical
signals (such as development of a premature beat; Fig-
ure S3B, left) or only in one (development of EADs noted
only in the membrane potential signal; Figure S3B, right);
both events were induced by application of ATX-II (30 nM).
Evaluation of CPVT2-hiPSC-CMs with GCaMP5G
Finally, we evaluated the ability to use GCaMP5G for study-
ing calcium-handling properties in diseased hiPSC-CMs. To
this end, we focused on CPVT, a familial arrhythmogenic
disorder caused by unstable sarcoplasmic-reticulum (SR)
Ca2+ storage, leading to exercise-induced ventricular ar-
rhythmias and sudden cardiac death (Katz et al., 2009).
The dominant form of CPVT (type1) stems frommutations
in the cardiac ryanodine receptor gene (RyR2), while the
less common recessive form (CPVT2) is due to mutations
in the calsequestrin gene (CASQ2) (Katz et al., 2009). In
both cases, arrhythmias are thought to result from diastolic
SR Ca2+ leak, leading to DADs and triggered arrhythmias.
While we previously modeled CPVT-1 using patient-spe-
cific hiPSC-CMs (Itzhaki et al., 2012), we chose to focus on
the more malignant, recessive form of the disease. We
therefore reprogrammed fibroblasts from a patient who is
part of a large family diagnosed with CPVT-2, due to the
homozygous D307H missense mutation in CASQ2 (Lahat
et al., 2001). The generated CPVT2-hiPSC colonies ex-
hibited characteristic morphology (Figure 6A), stained
positively for pluripotency markers (Figure S4A), gave rise
to cell derivatives of all three germ layers in differentiating
EBs (Figure S4B), showed silencing of the three retroviral
transgenes (Figure S4C), and showed reactivation of endog-
enous pluripotency genes (Figure S4D). Finally, genomic
analysis confirmed the presence of theCASQ2homozygous
D307Hmutation in the generated hiPSCs (Figure S4E). The
CPVT2-hiPSCs were then coaxed to differentiate into
cardiomyocytes. Immunostaining studies confirmed the
positive staining of the CPVT2-hiPSC-CMs for sarcomeric
a-actinin and cTnI (Figure 7A) and gene expression analysis
revealed the expression of cardiac-specific transcription
factors (NKX2.5) and structural genes (MLC-2V, MYH-6,
and MYH-7) and downregulation of the pluripotent genes
by these cells (Figure 7B).
Lentiviral transduction resulted in robust expression of
GCaMP5G by the CPVT2-hiPSC-CMs and allowed us
to monitor their intracellular calcium transients. When
compared to healthy control hiPSC-CMs (Figure 7C), the
CPVT2-hiPSC-CMs displayed marked arrhythmogenic ac-
tivity (Figure 7D). This abnormal activity, noted in 20%590 Stem Cell Reports j Vol. 5 j 582–596 j October 13, 2015 j ª2015 The Aof the CPVT2-hiPSC-CMs (n = 111), ranged from localized
intracellular diastolic calcium release events (Figure 7D,
top) to development of double-humped signals (Figure 7D,
second panel) and, finally, to marked arrhythmogenic ac-
tivity (Figure 7D, bottom two panels). Since arrhythmias
in CPVT patients are associated with exercise or emotional
stress, we next treated the CPVT2-hiPSC-CMs with isopro-
terenol (1 mM). Consistent with the clinical phenotype,
isoproterenol led to the development of significant
arrhythmias (Figure 7E) in 54% of the cells that were not
arrhythmogenic at baseline (n = 9).DISCUSSION
To fulfill the potential of the hiPSC technology for several
cardiovascular applications, methods should be developed
for efficient, long-term, and large-scale functional pheno-
typing of hiPSC-CMs. The successful utilization of geneti-
cally encoded fluorescent indicators in the neuroscience
field (Akemann et al., 2010; Cao et al., 2013; Grienberger
and Konnerth, 2012; Looger and Griesbeck, 2012; Tian
et al., 2009) and initial reports using similar GEVIs (Ley-
ton-Mange et al., 2014) and GECIs (Chong et al., 2014) in
hESC-CMs suggest that similar approaches could also prove
useful for studying different hiPSC-CMs.
Here, we combined the use of ArcLight and GCaMP5G
with hiPSC technology tomonitor the electrophysiological
and calcium-handling properties of healthy and diseased
hiPSC-CMs. Our results demonstrate the ability to robustly
acquire and analyze optically derived APs and intracellular
calcium transients from the hiPSC-CMs through either
transient or stable expression of ArcLight or GCaMP5G.
We also showed the advantages of using these genetically
encoded reporters in comparison to traditional voltage-
and calcium-sensitive dyes in terms of their significant
photostability, superior signal-to-noise ratio and minimal
cellular-toxicity properties. These properties allowed us
to obtain continuous, high-quality stable optical signals
from the same hiPSC-CMs for both short-term recordings
(hours) and repeated cellular phenotyping over several
days.
The aforementioned qualities allowed monitoring
changes in AP and calcium-handling properties and the
development of arrhythmias in hiPSC-CMs in response to
application of various drugs and in the setting of different
genetic disorders. First, we showed the potential of
ArcLight-hiPSC-CMs for screening the effects of drugs
known to prolong APD due to their hERG channel (IKr)-
blocking activity (‘‘QT screening’’). Drug-induced AP pro-
longation, leading to life-threatening arrhythmias, repre-
sents the single most important reason for withdrawal of
already approved drugs from the market (Roden, 2004).uthors
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Our results revealed the ability of ArcLight-based analysis
to robustly identify APD prolongation in the hiPSC-CMs,
as well as markers of arrhythmogenicity (EADs and trig-
gered beats), following application of a variety of QT-pro-
longing agents.
Next, we provided evidence for the potential of nilotinib
(a TKI used to treat multiple cancers) to prolong AP and
induce arrhythmias in human cardiomyocytes. This
finding may be important not only because of the clinical
importance of TKIs but also because of the suggestedmech-
anism underlying APD prolongation by these agents, as
suggested in a recent canine study (Lu et al., 2012), which
involves interaction with multiple currents and is not im-
mediate. This highlights the potential advantages of using
ArcLight-hiPSC-CMs over traditional heterologous expres-
sion systems used for QT screening (that evaluate only a
single current) and even over intracellular recording of
hiPSC-CMs, since ArcLight imaging allows us to follow
AP properties in the same cell over time. Finally, we also
showed the ability to use GCaMP5G (alone or combine
with voltage-imaging) to detect drug-induced alterations
in the calcium-handling properties of human cardiomyo-
cytes leading to arrhythmias.
In addition to studying drug effects on AP and calcium
handling, we also showed the potential of using genetic
reporters for studying inherited arrhythmogenic disorders.
To this end, we utilized a previously established LQTS2
patient-specific line (Itzhaki et al., 2011a) and also gener-
ated a new hiPSC line from a patient with CPVT2 due to
a homozygous CASQ2 mutation. Importantly, our results
confirmed the ability of ArcLight imaging to recapitulate
the LQTS clinical phenotype (AP prolongation and the
development of EADs and triggered arrhythmias) and ofFigure 6. GCaMP5G Expression and Calcium Imaging of hiPSC-CMs
(A) Lentiviral transduction of hiPSC-CMs led to robust GCaMP5G expres
intensity concomitant with the rise in intracellular calcium concentr
(B) Line-scan imaging (using the red line in A) showing typical optic
(C–E) Optical calcium transients (C) acquired simultaneously from the s
(black tracing) and Rhod-3 (red tracing). The transients displayed si
slightly longer in the GCaMP5G signal (*p < 0.01) (D). SNR values were
when compared to the Rhod-3 signals (E).
(F) Continuous optical calcium recordings from the GCaMP5G-hiPSC-
(lower left) and significantly less attenuation in fluorescent intensity
(G) Drug testing using GCaMP5G-hiPSC-CMs. Isoproterenol (1 mM) led t
well as a shorter decay and rise times of the calcium transient (*p <
(H) Application of ouabain led to a dose-dependent arrhythmogenic ac
humped transients, to sustained triggered activity.
(I) ArcLight-hiPSC-CMs were loaded with Rhod-3. Combined line-sca
(black) and intracellular calcium transient (red).
(J) Combined voltage (black tracing) and calcium (red) imaging usin
Error bars represent SEM.
See also Figure S3B.
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handling and the development of arrhythmias).
The genetically encoded reporters used in this study also
possess certain limitations. The optical fluorescent signals
only allow monitoring of relative changes in membrane
potential and intracellular calcium levels and cannot pro-
vide absolute values. Moreover, although previous valida-
tion studies using simultaneous intracellular patch-clamp
recordings and ArcLight fluorescence-imaging in neurons
(Jin et al., 2012) and in hESC-CMs (Leyton-Mange et al.,
2014) revealed a relative good correlation in identifying
single APs, in the overall morphology of the AP, in
measuring APD, and in the ability to detect arrhythmias,
it also revealed an inherent limitation in the frequency
response of ArcLight. This was manifested by some delay
at fast frequencies, such as occuring during the rapid depo-
larization (phase 0) of the AP in cardiomyocytes. In the case
of GCaMP5G, we also observed a short delay in evaluating
the rise time of the intracellular calcium transient when
compared to Rhod-3-AM fluorescent-dye imaging. This
minimal delay will probably not be very significant for
future studies. Ongoing efforts in the field are focused on
generating newer generation of GEVIs and GECIs with
superior temporal properties that may potentially solve
this drawback.
Despite these limitations, our results reveal the unique
potential of combing the hiPSC technology with GEVIs
and GECIs for several cardiovascular applications. This
unique potential stems from the ability to follow the func-
tional properties of hiPSC-CMs over time, from the poten-
tial for large-scale analysis and high-throughput screening,
the ability to study different excitation-contraction
coupling processes simultaneously (electrophysiology,sion and cyclic changes in the cell fluorescence with an increase in
ation. Scale bars, 20 mm.
al intracellular calcium transients.
ame cells (n = 16 in three independent experiments) using GCaMP5G
milar general appearance and decay times, while the rise time was
significantly higher (*p < 0.001) for the GCaMP5G optical tracings
CMs (top). The GCaMP5G signals displayed higher mean amplitude
over time when compared to Rhod-3 signals. *p < 0.01.
o a significant increase in the beating rate (shorter cycle-length), as
0.05, **p < 0.01, n = 21 in three independent experiments).
tivity, ranging from local calcium release events, double- and triple-
n imaging allowed simultaneous recording of both the optical AP
g hiPSC-CMs transduced to express both Arch(D95N) and GCaMP5G.
uthors
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Figure 7. GCaMP5G-Based Calcium Imaging of CPVT2-hiPSC-CMs
(A) Differentiation of the CPVT2-hiPSCs (left; scale bar, 100 mm) into cardiomyocytes positively stained for sarcomeric a-actinin (middle)
and cTnI (right). Scale bars, 20 mm. See also Figure S4.
(B) qPCR analysis of the CPVT2-hiPSC-CMs showing expression of cardiac-specific genes (NKX2.5, MLC-2V, MYH-6, and MYH-7) and
downregulation of OCT4 and NANOG. Experiments included three biological replicates measured as two technical replicates.
(C and D) GCaMP5G optical calcium imaging of healthy control (C) and CPVT2 (D) hiPSC-CMs. The CPVT2-cardiomyocytes were highly
arrhythmogenic, displaying diastolic local calcium release events (top), double-humped signals (second panel), and sustained arrhyth-
mias (bottom).
(E) An example of new arrhythmias in a CPVT2-hiPSC-CM (bottom) caused by isoproterenol.
Error bars represent SEM.calcium handling, and mechanics), and the potential to
combine the described methods with other techniques
(such as single-cell gene expression analysis). Moreover,
long-term fluorescent analysis can be combined with tradi-
tional electrode-based extracellular potential recordings,
for example, by culturing hiPSC-CMs on multielectrode
arrays (MEA) culture plates (Zwi et al., 2009). This will allow
the advantage of using the MEA technique for analyzing
extracellular potentials and for studying the tissue’s
syncytial properties, while obtaining, through the use of
the GEVIs and GECIs, data at higher spatial resolution
and functional information regarding the intracellular
properties (membrane potential and calcium transients).
The described approach could also bring a unique value
to questions related to hiPSC-CMs differentiation andStem Cellmaturation. This should allow non-invasive monitoring
of the effects of interventions aiming to augment car-
diac-lineage differentiation, to direct differentiation to-
ward specific cardiomyocyte subtypes and to induce
hiPSC-CMs maturation. The advantages of combing pa-
tient/disease-specific hiPSC-CMs and genetically encoded
reporters (as exemplified here for the LQTS and CPVT syn-
dromes) should provide a unique tool to study inherited
cardiac disorders for better mechanistic understanding
and for screening of existing and novel therapeutic strate-
gies. Similarly, although we focused in the current study
on the potential applications in the field of safety pharma-
cology (QT screening), the same concepts could be
expanded for other drug development and target valida-
tion approaches.Reports j Vol. 5 j 582–596 j October 13, 2015 j ª2015 The Authors 593
EXPERIMENTAL PROCEDURES
Please also refer to the Supplemental Experimental Procedures.Human-Induced Pluripotent Cells Derivation
Dermal fibroblasts were obtained from a healthy individual and
from a patient with CPVT2. All studies were approved by the IRB
(Helsinki) committee of Rambam Medical Center. Fibroblasts
were reprogrammed to generate hiPSC clones by retroviral delivery
of three reprogramming factors (SOX2, KLF4, and OCT4) as previ-
ously described (Itzhaki et al., 2011b).Propagation of hiPSCs and Cardiomyocyte
Differentiation
Colonies of hiPSCs were propagated on Matrigel using mTeSR-1
(StemCell Technologies). Cells were passaged by dissociation
with 0.5 mM EDTA every 4–6 days. For cardiomyocyte induction,
a differentiation medium containing RPMI-1640, 2% B27 supple-
ment minus insulin (Life Technologies), 1% penicillin/strepto-
mycin, and 6 mM CHIR99021 (Stemgent) was used for 2 days. On
day 2, medium was changed to RPMI/B27 (without CHIR), and
on days 3–4, it was supplemented with 5 mM IWR-1. The resulting
beating monolayers (30–50 days of differentiation) were enzymat-
ically dissociated into small clusters or single cardiomyocytes
using TrypLE and then plated on matrigel-coated coverslips for
characterization.Lentiviral Transduction of the ArcLight and
GCaMP5G Transgenes
Transient Expression in hiPSCs-CMs
pLV-CAG-ArcLight and pLV-TroponinT-GCaMP5 plasmids were
kindly provided by David Milan (Massachusetts General Hospital)
and John Epstein (University of Pennsylvania), respectively.
pLV-GCaMP5G-ArchD95N was obtained from Addgene (plasmid
42168). HEK293Tcells were transfected with 4.5 mg of the relevant
plasmid, 3 mg of NRF packaging plasmid, and 1.5 mg of the VSVG
plasmid using jetPEI reagent (Polyplus). Fresh virus-containing
media were collected at 48 and 72 hr and used for two rounds
of infections of dissociated hiPSC-CMs to improve transduction
efficiency. Viral dosages for the ArcLight, GCaMP5, and
GCaMP5+D95N plasmids were 7 3 105 TU/ml, 1.3 3 106 TU/ml,
and 3.4 3 106 TU/ml, respectively. No cellular adverse effects
were noted following transduction.
Establishing Stable ArcLight-hiPSC Clones
Undifferentiated hiPSCs were infected in the same manner with
the pLV-CAG-ArcLight lentiviral vector. Positive ArcLight-express-
ing colonies were identified (green fluorescence), isolated by
microdissection, and further propagated. This enrichment process
was repeated at 3 and 4 weeks.
Pharmacological Studies
E4031 (500 nM), ATX-II (30 nM; both from Alomone labs),
ouabain (0.5–1 mM), sotalol (20 mM), isoproterenol (1 mM), and
erythromycin (30 mM) were dissolved in H2O, while chromanol
293B (30 mM), cisapride (100 nM; all from Sigma), and nilotinib
(1 mM; Adooq Bioscience) were dissolved in DMSO. Identical
DMSO amounts (0.1%) were used as vehicle controls.594 Stem Cell Reports j Vol. 5 j 582–596 j October 13, 2015 j ª2015 The AOptical Imaging of ArcLight or GCaMP5G-Expressing
hiPSC-CMs
A Zeiss LSM700 laser-scanning confocal microscope was used
to measure the fluorescence intensity of ArcLight, GCaMP5G, or
Rhod-3-AM. To derive a dynamic display depicting the changes
in fluorescence intensity over time, the frame-acquisition mode
was used. For acquisition of optical APs and calcium transients,
the line-scanmodewas used. For drug studies, recordings were per-
formed 15 min after adding the different drugs to the Tyrode’s so-
lution, except for nilotinib (60–90 min).
Dual Calcium Indicator Imaging
GCaMP5G and Rhod-3-AM were excited simultaneously by the
488- and 555-nm lasers, respectively. Emission was split by a vari-
able secondary dichroic beamsplitter set into two photomulti-
pliers. For GCaMP5G, emission was short-pass filtered at 555 nm;
while for Rhod-3, emission was long-pass filtered at 560 nm.
Combined Calcium and Voltage Imaging
For simultaneous ArcLight and Rhod-3 imaging, the setup
described above was used. For dual imaging of GCaMP5G and
Arch(D95N), hiPSC-CMs were excited simultaneously by 488-
and 555-nm lasers, respectively. Emission was split and short-
passed filtered at 555 nm for GCaMP5 and long-passed filtered at
640 nm for Arch(D95N).
Data Analysis
Optical APs
ArcLight recordings were analyzed using a custom-written Matlab
program. APD90 was measured as the interval between the timing
of 50%maximal upstroke amplitude until the time point of 90%of
repolarization. The peak-to-peak interval was used to determine
beating rate.
Optical Calcium Transients
GCaMP5G and Rhod-3 recordings were analyzed using the
Clampfit10 program (Molecular Devices) to measure: (1) rise
time, defined as the interval from the timing of the signal at 10%
of its maximal amplitude to the peak, (2) decay time, the interval
from the timing of the peak to the point where calcium level is
reduced to 10%of the peak amplitude, and (3) beating rate. Optical
calcium transients are presented as F/F0, where F0 is the resting
diastolic fluorescence.
Statistical Analysis
Continuous variables are reported as mean ± SEM. Categorical
variables are expressed as frequencies. Categorical differences
between groups were evaluated by the chi-square test. Differences
between group means were compared using an unpaired Stu-
dent’s t test. For drug studies, differences between baseline and
post-drug application values were compared using a paired Stu-
dent’s t test. A value of p < 0.05 was considered statistically
significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, one table, and five movies and can be
found with this article online at http://dx.doi.org/10.1016/j.
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